Regenerative Medical Technology (RMTG) Enterprise Value (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Enterprise Value of -$1.1 million for Q1 2026, up 13.2% year-over-year from -$937638.1 in Q1 2025, and down 10.95% quarter-over-quarter from -$956718.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Enterprise Value (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Enterprise Value history runs 10 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 13.2% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$1.1 million (up 13.2% YoY), while the FY2025 annual figure was -$956718.0, up 17.94% from the prior year.
- Enterprise Value for Q1 2026 stood at -$1.1 million, down from -$956718.0 in the prior quarter.
- The five-year high for Enterprise Value was -$530540.0 in Q4 2023, with the low at -$2.5 million in Q1 2022.
- The 5-year median for Enterprise Value is -$1.2 million (2025), against an average of -$1.3 million.
- Peak annual rise in Enterprise Value reached 90.65% in 2022, while the deepest fall reached 212.44% in 2022.
- Regenerative Medical Technology's Enterprise Value stood at -$1.6 million in 2022, then surged by 67.75% to -$530540.0 in 2023, then tumbled by 119.74% to -$1.2 million in 2024, then climbed by 17.94% to -$956718.0 in 2025, then dropped by 10.95% to -$1.1 million in 2026.
- Business Quant data shows RMTG's Enterprise Value at -$1.1 million in Q1 2026, -$956718.0 in Q4 2025, and -$1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 2.12 Bn |
| 10 | Regenerative Medical Technology | 814,616.00 | -246,832.00 | 1.77 Mn | -1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.06 Mn |
| Dec 31, 2025 | -956,718.00 |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.61 Mn |
| Mar 31, 2025 | -1.22 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Sep 30, 2024 | -836,427.00 |
| Jun 30, 2024 | -617,093.00 |
| Mar 31, 2024 | -579,352.00 |
| Dec 31, 2023 | -530,540.00 |
| Sep 30, 2023 | -1.14 Mn |
| Jun 30, 2023 | -1.23 Mn |
| Mar 31, 2023 | -1.64 Mn |
| Dec 31, 2022 | -1.65 Mn |
| Sep 30, 2022 | -1.77 Mn |
| Jun 30, 2022 | -1.92 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.98 Mn |
| Sep 30, 2021 | -18.93 Mn |
| Jun 30, 2021 | -10.49 Mn |